Main Uses and Therapeutic Applications

Veracal is a calcium channel blocker belonging to the phenylalkylamine class. Its primary therapeutic function is to inhibit the influx of calcium ions into cardiac muscle cells and smooth muscle cells of the coronary and systemic arteries. This mechanism of action allows for the management of several cardiovascular conditions.

Chronic Stable Angina Pectoris

Veracal is used for the long-term management of angina pectoris, a condition characterized by chest pain or discomfort. By dilating the coronary arteries and reducing the heart's demand for oxygen, it helps decrease the frequency and severity of angina attacks.

Vasospastic Angina

This medication is also applied in the treatment of vasospastic (Prinzmetal's or variant) angina. It works by preventing the spontaneous spasms of the coronary arteries that restrict blood flow to the heart muscle.

Essential Hypertension

Veracal is utilized in the management of high blood pressure (hypertension). It lowers blood pressure by relaxing the blood vessels, which reduces the resistance against which the heart must pump, thereby facilitating easier blood flow throughout the body.

Cardiac Arrhythmias

In certain instances, Veracal is used to control specific types of irregular heartbeats, particularly supraventricular tachyarrhythmias. It helps regulate the heart rate by slowing the electrical conduction through the atrioventricular (AV) node.

---

Expected Benefits

The primary clinical objective of treatment with Veracal is the stabilization of cardiovascular function. The benefits associated with its use include:

• Reduction in Chest Pain: Improved oxygen supply to the myocardium helps minimize the occurrence of angina symptoms.
• Blood Pressure Regulation: Consistent use aids in maintaining blood pressure within a target range, reducing the long-term strain on the cardiovascular system.
• Improved Exercise Tolerance: By managing angina and heart rate, patients may experience an increased ability to perform physical activities without discomfort.
• Heart Rate Stabilization: The modulation of electrical impulses helps maintain a more consistent and appropriate heart rhythm.

Regulatory References

1. NIH MedlinePlus overview of Verapamil

Who Can and Cannot Use Veracal?

Eligibility for Veracal (Verapamil Hydrochloride) is strictly defined by regulatory documents, primarily based on the patient's existing heart condition and physiological function.

Contraindicated Populations (Must Not Use)

Veracal is absolutely contraindicated in patients with specific severe heart conditions, as this may lead to serious adverse events. These conditions include:

• Severe Left Ventricular Dysfunction (e.g., severe heart failure).
• Cardiogenic Shock or Hypotension (systolic pressure below 90 mm Hg).
• Second- or Third-Degree AV Block or Sick Sinus Syndrome (unless a functional artificial pacemaker is present).
• Atrial Fibrillation/Flutter with an Accessory Bypass Tract (e.g., Wolff-Parkinson-White Syndrome).

---

Restricted and Conditional Use

Use is allowed but requires special caution and monitoring in specific populations:

• Impaired Organ Function: Patients with impaired hepatic or renal function require reduced doses and careful titration due to the drug's metabolism and clearance.
• Pediatric Use: The safety and effectiveness of oral Veracal formulations have not been established and are generally not recommended for children. However, intravenous use is established for specific tachycardias in pediatric patients.
• Pregnancy and Lactation: Use during pregnancy is generally restricted (Category C) and is only recommended when the potential benefit outweighs the risk to the fetus. Nursing mothers are advised to discontinue breastfeeding as Veracal is excreted into human milk.

Veracal's (Verapamil Hydrochloride) interaction profile is defined by its documented effects on drug metabolism and cardiac function, as described in official government labeling. These interactions necessitate specific restrictions and exposure monitoring when co-administered with other substances.

Pharmacokinetic and Exposure-Altering Interactions

Verapamil is documented as an inhibitor of the CYP3A4 enzyme and the P-glycoprotein (P-gp) transporter. This status means that Veracal may increase the systemic plasma concentration and exposure (AUC/Cmax) of many co-administered drugs that are substrates of these pathways, including certain statins (e.g., Simvastatin) and Digoxin. Conversely, co-administration with strong CYP3A4 inducers, such as Rifampin, is documented to markedly reduce Verapamil's own bioavailability and plasma levels.

Pharmacodynamic and Timing Constraints

The medicine's effect as a Calcium Channel Blocker creates the potential for additive negative pharmacodynamic effects on heart rate, AV conduction, and/or contractility when combined with certain cardiovascular agents. Therefore, co-administration of intravenous Beta-blockers in close proximity to Veracal is prohibited. Furthermore, a strict timing separation is required for some drugs; for example, Disopyramide must not be administered within 48 hours before or 24 hours after Veracal. Official documentation also advises avoiding substances like Grapefruit Juice and noting that Veracal increases blood Ethanol (alcohol) concentration.

How Veracal Works

Veracal exerts its pharmacodynamic action by targeting specific receptor- or enzyme-mediated signaling within distinct biological systems. The mechanism is organized across three mechanistic domains, focusing exclusively on cellular and systemic physiological modulation.

Modulating Receptor-Mediated Signaling

This process involves Veracal directly engaging a key family of target receptors, influencing systems where specific neurotransmitters or mediators dominate. This interaction initiates downstream signaling sequences that result in the modulation of pathway activity, specifically reducing the duration or magnitude of specific signaling events.

Regulating Pathway Activity

Veracal is characterized by its ability to enact targeted pathway adjustment. It modifies early molecular steps and influences established feedback regulation mechanisms within these pathways. The consequence of this regulation is a reduction in the concentration or duration of specific mediator activity, inducing changes in regulatory elements that favor a balanced steady state.

Influencing Dysregulated Processes

This domain describes the action within complex mechanistic cascades where multiple layers of pathway activation occur. By regulating overactive or dysregulated cellular processes, the overall effect establishes a systemic shift in homeostatic parameters, modulating pathway activity toward a defined physiological set point.

Veracal (Verapamil Hydrochloride) is administered through two pathways: the oral route for chronic, maintenance regimens, and the intravenous (IV) route for acute clinical needs.

Oral Administration and Dosing

Oral formulations are provided as immediate-release (IR) and extended-release (ER) forms, which dictate the dosing frequency. Immediate-release tablets are typically taken three or four times a day in doses ranging from 40 mg to 120 mg per administration. Extended-release tablets and capsules, conversely, are typically taken once daily or twice daily, with starting doses often between 120 mg and 240 mg. The maximum daily total dose for oral use generally does not exceed 480 mg. Oral forms are generally recommended to be taken with or shortly after meals.

Crucially, extended-release tablets and capsules must be swallowed whole and must not be crushed or chewed to ensure the proper release of the active substance. Following prolonged use, the medicine should be tapered off gradually upon discontinuation.

Intravenous (IV) Use and Special Conditions

The IV injection is reserved for acute, supervised care. The typical initial bolus dose for adults is 5 mg to 10 mg (or 0.075-0.15 mg/kg), administered as a slow injection over at least two minutes. A second bolus dose may be given 30 minutes later if necessary. IV administration must be performed under continuous ECG and blood pressure monitoring.

Dose adjustments are required for certain populations. For older adults, the IV injection must be administered over at least three minutes. In cases of hepatic impairment, a substantial reduction in the initial oral dose (e.g., to 40 mg two or three times daily) is required due to altered clearance.

Veracal: Recent Clinical Evidence

Research Evidence / Overview of Studies

Mechanism of Action: Studies on Cellular Pathways

Studies have explored the compound's potential biological action. Research examined the drug's interaction with the target enzyme in both in vitro (laboratory) and animal models to investigate the compound's behavior in these systems.

Efficacy in Joint Conditions

Primary Efficacy Trials

A Phase III, multi-center study evaluated the drug's role in the management of moderate-to-severe joint inflammation. The primary goal was to see if the treatment was associated with changes in an internationally recognized disease activity score after 12 weeks. Secondary endpoints included whether it was associated with changes in joint mobility and function scores, as measured by patient-reported outcomes.

The key study results indicated that the group receiving the study drug suggested a potential difference compared to placebo in achieving the primary endpoint. The study also assessed the onset of observable changes in symptom reporting, with patients recording their pain levels at regular intervals.

Long-term Data and Potential for Prolonged Change

Research on extended use investigated the potential for a prolonged change in inflammation markers and patient function over a 52-week period. The results were primarily observational after the initial controlled phase. Some follow-up research has explored whether a lower pain score was observed at the end of the first year of treatment.

Safety and Tolerability Profiles

Short-term Safety Analysis

Across the initial clinical trials, the most commonly reported side effects included mild gastrointestinal upset and temporary headaches. In the trials, these were generally reported as mild and resolved without specific intervention. There was no indication of severe adverse events occurring at a statistically different rate between the treatment and placebo groups.

Investigation of Long-term Safety

Research has investigated the long-term safety profile, and the study did not observe new safety signals during the evaluation period (up to 52 weeks). Specific monitoring focused on liver enzyme levels and potential cardiovascular indicators.

Combination Therapy Research

Research evaluated whether the combination was associated with changes in overall disease activity when the study drug was used alongside a standard disease-modifying anti-rheumatic drug (DMARD) in patients who had not responded adequately to DMARDs alone.

These findings suggest a need for further investigation regarding the specific patient groups who might experience the most measurable changes from this combination approach.

Common questions about Veracal (FAQ)

---

Q: What if I forget to take my Veracal dose?

Official patient instructions describe the process for a missed dose. If the dose is remembered soon after it was missed, it may be taken. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped entirely, and the regular schedule should be resumed. It is specified that the dose must not be doubled to make up for a missed one.

---

Q: Are there any specific vitamins or supplements that interact with Veracal?

Regulatory documents indicate that multivitamins containing minerals may potentially decrease the effects of Veracal. Because many non-prescription products may interact with drug metabolism, official product information suggests informing a healthcare professional about all co-administered products, including any vitamins and herbal supplements.

---

Q: Is Veracal safe for older adults (seniors)?

Official information indicates that Veracal may take longer to clear from the body in older adults, as the elimination half-life may be prolonged. This pharmacokinetic characteristic means use in this population warrants close monitoring, as noted in official guidance.

---

Q: Is it safe to take Veracal with common pain relievers like ibuprofen?

Co-administration with nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, may potentially cause blood pressure to increase. Regulatory guidance suggests that co-administration may warrant increased blood pressure monitoring.

---

Q: Can Veracal cause serious side effects that I should know about?

Official documents list critical safety warnings and contraindications. Serious adverse reactions include severe decreases in blood pressure (hypotension), certain severe heart rhythm disturbances (second- or third-degree AV block), and new or worsening congestive heart failure.

---

Q: Does Veracal interact with herbal remedies like St. John's Wort?

Yes, regulatory sources specifically mention St. John's wort, which is classified as a strong enzyme inducer. This herbal remedy can affect the way Veracal is processed in the body, and official guidance recommends consulting a healthcare professional prior to co-administration.

---

Q: What are the signs of an allergic reaction to Veracal?

Signs of a severe hypersensitivity reaction, as described in official documents, may include symptoms like hives on the skin, rash, itching, swelling of the face, difficulty breathing, or severe dizziness.

---

Q: How is Veracal eliminated from the body?

According to the official product information, the medicine is primarily eliminated after being broken down into metabolites. Approximately 70% of the dose is excreted in the urine, and 16% or more is eliminated through the feces.

---

Q: Does Veracal cause weight gain or weight loss?

Weight changes are not commonly listed as a direct side effect. However, swelling in the hands, ankles, or feet (edema) is a reported side effect associated with the drug class that can cause an increase in body weight due to fluid retention.

---

Q: Does Veracal affect sleep or cause insomnia?

Official side effect data lists sleep disturbance as a common effect, occurring in 1% to 10% of patients in clinical trials. Insomnia (difficulty sleeping) has also been reported in postmarketing experience.

---

Q: Can Veracal be taken with blood pressure medication?

Veracal is frequently used alongside other blood pressure medicines. However, because both can lower blood pressure, co-administration may increase the risk of excessive blood pressure lowering. These situations warrant careful medical monitoring as described in the product label.

---

Q: Does Veracal affect mood or cause mood swings?

Official adverse event information lists mood changes, including emotional depression, as an uncommon side effect (0.1% to 1% frequency). Confusion and other psychiatric symptoms have been reported in postmarketing surveillance.

---

Q: Can Veracal be used by people with kidney problems?

Veracal should be used with caution and close monitoring in individuals who have impaired renal (kidney) function. This caution is specified in official warnings and precautions sections.

---

Q: Does Veracal have a risk of dependence or addiction?

Veracal is not classified as a controlled substance by regulatory agencies and is not generally associated with dependence or addiction risk. Official guidance advises patients to gradually reduce the dose if discontinuing the medicine after prolonged use.

---

Q: What are the long-term effects of taking Veracal?

Research has investigated the long-term safety profile of Veracal, typically up to 52 weeks, focusing on monitoring liver function and cardiovascular indicators. The studies did not observe new safety signals during the evaluation period. Available data indicates the drug is not classified as a human carcinogen by the state of California (Proposition 65).

---

Q: Does Veracal cause dry mouth?

Dry mouth has been reported as a side effect within the gastrointestinal system during postmarketing surveillance of the drug.

---

Q: Is it okay to take Veracal with antacids?

Official interaction information notes that the use of calcium-containing products, such as some antacids (e.g., calcium carbonate), may decrease the effectiveness of Veracal. Co-administration with these products warrants medical monitoring, as noted in the official information.

---

Q: Why do doctors use Veracal for certain conditions?

Veracal is used for certain conditions because its documented mechanism of action as a Calcium Channel Blocker allows it to regulate the heart's electrical conduction system. This action helps to control heart rhythm and promotes the relaxation of blood vessel walls.

---

Q: How quickly does Veracal start working?

The time it takes to reach peak concentration in the bloodstream depends on the formulation used. Immediate-release forms generally reach peak concentration in 1–2 hours. Sustained-release formulations take longer, typically reaching peak concentration between 6 and 11 hours.

---

Q: What should I do if I think I'm having a side effect from Veracal?

Official guidance states that individuals experiencing side effects contact their healthcare provider or pharmacist for guidance. If symptoms are severe or there are signs of a serious reaction, immediate medical attention may be necessary.

---

Q: Is it normal to feel tired after starting Veracal?

Yes, fatigue and tiredness are listed in official documents as common side effects of Veracal, which were reported in 1% to 10% of patients during clinical trials.

Storage Conditions

Veracal (Verapamil Hydrochloride) must be stored at Controlled Room Temperature, which is officially defined as 20 C to 25 C (68 F to 77 F). The product must be kept away from excess heat and protected from moisture. Storage above 30 C is prohibited, and the medication must not be frozen.

Packaging and Stability

Tablets and capsules must be kept in the container it came in, tightly closed. For patient safety, the medicine must be kept out of the reach of children and pets, with regulatory guidance advising it should be stored locked up.

Disposal Requirements

Unused or expired Veracal must be disposed of in accordance with all local and national regulations. Patients should consult a healthcare professional for specific disposal instructions, as the medicine must not be flushed or released into the environment.